NASDAQ:GERN - Geron Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.65 -0.04 (-2.37 %)
(As of 03/25/2019 10:31 AM ET)
Previous Close$1.69
Today's Range$1.63 - $1.74
52-Week Range$0.95 - $6.99
Volume15,359 shs
Average Volume3.49 million shs
Market Capitalization$307.54 million
P/E Ratio-10.25
Dividend YieldN/A
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GERN



Sales & Book Value

Annual Sales$1.07 million
Book Value$0.95 per share


Net Income$-27,020,000.00
Net Margins-2,534.43%


Market Cap$307.54 million
Next Earnings Date5/9/2019 (Estimated)

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). The biopharmaceutical company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.22 million. Geron had a negative return on equity of 17.61% and a negative net margin of 2,534.43%. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

3 brokers have issued twelve-month target prices for Geron's shares. Their predictions range from $1.80 to $4.00. On average, they expect Geron's stock price to reach $3.0167 in the next twelve months. This suggests a possible upside of 82.8% from the stock's current price. View Analyst Price Targets for Geron.

What is the consensus analysts' recommendation for Geron?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Has Geron been receiving favorable news coverage?

News coverage about GERN stock has trended positive on Monday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Geron earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.

Are investors shorting Geron?

Geron saw a increase in short interest in February. As of February 28th, there was short interest totalling 39,887,553 shares, an increase of 2.0% from the February 15th total of 39,090,422 shares. Based on an average daily volume of 4,360,861 shares, the days-to-cover ratio is currently 9.1 days. Currently, 21.5% of the shares of the stock are short sold. View Geron's Current Options Chain.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Puma Biotechnology (PBYI), Incyte (INCY), Exelixis (EXEL), Dynavax Technologies (DVAX), Micron Technology (MU), BioMarin Pharmaceutical (BMRN), Anavex Life Sciences (AVXL), Amarin (AMRN) and Alibaba Group (BABA).

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 69)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)

Who are Geron's major shareholders?

Geron's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (8.34%), BlackRock Inc. (8.07%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.02%), Geode Capital Management LLC (1.02%) and Two Sigma Investments LP (0.53%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, New York State Common Retirement Fund, Bank of New York Mellon Corp, Jane Street Group LLC and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Geron company stock in the last year include Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.

Which major investors are buying Geron stock?

GERN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, BlackRock Inc., Two Sigma Investments LP, D. E. Shaw & Co. Inc., Ibex Investors LLC, Virtu Financial LLC and Northern Trust Corp. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.65.

How big of a company is Geron?

Geron has a market capitalization of $307.54 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.

What is Geron's official website?

The official website for Geron is

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

MarketBeat Community Rating for Geron (NASDAQ GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  343 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  620
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel